...
首页> 外文期刊>Future medicinal chemistry >The therapeutic potential of targeting the K(ir)1.1 (renal outer medullary K+) channel
【24h】

The therapeutic potential of targeting the K(ir)1.1 (renal outer medullary K+) channel

机译:靶向K(IR)1.1(肾外髓质K +)通道的治疗潜力

获取原文
获取原文并翻译 | 示例
           

摘要

K(ir)1.1 (renal outer medullary K+) channels are potassium channels expressed almost exclusively in the kidney andents the role of transporter play a role in the body's electrolyte and water balance. Potassium efflux through K(ir)1.1 complims and sodium channels that are the targets of known diuretics. Consequently, loss-of-function mutations in men and rodents are associated with salt wasting and low blood pressure. On this basis, K(ir)1.1 inhibitors may have value in the treatment of hypertension and heart failure. Efforts to develop small molecule K(ir)1.1 inhibitors produced MK-7145, which entered into clinical trials. The present manuscript describes the structure-activity relationships associated with this scaffold alongside other preclinical K(ir)1.1 blockers.
机译:K(IR)1.1(肾外外髓质K +)通道是几乎专门在肾脏中表达的钾通道,运输器在身体的电解质和水平衡中发挥作用。 通过K(IR)的钾渗透量1.1备管和钠通道,即已知利尿剂的靶标。 因此,男性和啮齿动物的功能丧失与盐浪费和低血压有关。 在此基础上,K(IR)1.1抑制剂可能具有治疗高血压和心力衰竭的价值。 开发小分子K(IR)1.1抑制剂的努力产生了MK-7145,其进入临床试验。 本发明的稿件描述了与该支架相关的结构 - 活性关系,以及其他突出的临床型K(IR)1.1阻断剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号